
Ciara M Kelly

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4499296/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine, 2017, 23, 703-713.	15.2	2,473
2	Moving beyond Karnofsky and ECOG Performance Status Assessments with New Technologies. Journal of Oncology, 2016, 2016, 1-13.	0.6	145
3	Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab. JAMA Oncology, 2020, 6, 402.	3.4	125
4	Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. , 2017, 5, 8.		111
5	The management of metastatic GIST: current standard and investigational therapeutics. Journal of Hematology and Oncology, 2021, 14, 2.	6.9	107
6	HER2: An emerging target in colorectal cancer. Current Problems in Cancer, 2018, 42, 560-571.	1.0	67
7	Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets. Nature Communications, 2022, 13, .	5.8	63
8	Genomic Profiling Identifies Association of <i>IDH1/IDH2</i> Mutation with Longer Relapse-Free and Metastasis-Free Survival in High-Grade Chondrosarcoma. Clinical Cancer Research, 2020, 26, 419-427.	3.2	60
9	Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. Nature Communications, 2022, 13, .	5.8	51
10	The genomics and therapeutics of HER2-positive gastric cancer—from trastuzumab and beyond. Journal of Gastrointestinal Oncology, 2016, 7, 750-762.	0.6	45
11	Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma—A New Look at an Old Drug. Oncologist, 2017, 22, 1102-1106.	1.9	39
12	Targeted Therapy in Older Patients With Solid Tumors. Journal of Clinical Oncology, 2014, 32, 2635-2646.	0.8	36
13	A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor. Investigational New Drugs, 2019, 37, 282-290.	1.2	32
14	Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma. Nature Communications, 2022, 13, .	5.8	21
15	Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center. , 2022, 10, e004149.		20
16	Clinical Outcome of Leiomyosarcomas With Somatic Alteration in Homologous Recombination Pathway Genes. JCO Precision Oncology, 2020, 4, 1350-1360.	1.5	18
17	The emerging role of immunotherapy for the treatment of sarcoma. Journal of Surgical Oncology, 2021, 123, 730-738.	0.8	16
18	Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor. Journal of Clinical Oncology, 2022, 40, 997-1008.	0.8	13

CIARA M KELLY

#	Article	IF	CITATIONS
19	HLA Genotyping in Synovial Sarcoma: Identifying HLA-A*02 and Its Association with Clinical Outcome. Clinical Cancer Research, 2020, 26, 5448-5455.	3.2	12
20	Long-term Follow-up and Patterns of Response, Progression, and Hyperprogression in Patients after PD-1 Blockade in Advanced Sarcoma. Clinical Cancer Research, 2022, 28, 939-947.	3.2	10
21	From Shelf to Bedside—Wearable Electronic Activity Monitoring Technologies Might Assist Oncologists in Functional Performance Status Assessment of Older Cancer Patients. Clinical Colorectal Cancer, 2017, 16, e115-e118.	1.0	9
22	Proton radiotherapy for recurrent or metastatic sarcoma with palliative quad shot. Cancer Medicine, 2021, 10, 4221-4227.	1.3	8
23	Case Report: Response to Regional Melphalan via Limb Infusion and Systemic PD1 Blockade in Recurrent Myxofibrosarcoma: A Report of 2 Cases. Frontiers in Oncology, 2021, 11, 725484.	1.3	4
24	Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors. Clinical Cancer Research, 2022, 28, 1507-1517.	3.2	3
25	Interpreting Nonrandomized Clinical Trial Data in Low-Grade Sarcoma: Differentiating Clinical Benefit From Indolent Disease Is Key. JCO Precision Oncology, 2022, , .	1.5	1